[PDF] Résultats de l’étude Intelligence - La Tribune

Recherche sur un modèle dautorité de régulation dans lUnion

2 janv. 2019 30 R. RAMBAUD L?institution juridique de la régulation. Recherches sur les rapports entre droit administratif.

Résultats de l’étude Intelligence - La Tribune

INFORMATION PRESSE Mercredi 30 mars 2016 Résultats de l’étude Intelligence 360 Le marché pharmaceutique mondial en progression de 89 par rapport à 2014 La France passera de la 5ème à la 8ème place mondiale à horizon 2020 Marché mondial : retour de la croissance dans les pays matures

Delivering on the Potential of Biosimilar Medicines

The study is based on independent research and analysis undertaken by the IMS Consulting Group that was funded by Novartis The interpretation of the results of the research and analysis and preparation of this report was undertaken independently by the IMS Institute for Healthcare Informatics also with funding by Novartis

June 2015 The Role of Generic Medicines in Sustaining

Le Marché Pharmaceutique dans le Monde et en France : Bilan

IMS Health 2011 • Une croissance mondiale qui revient tirée par les pays émergents et les produits de spécialité • Un marché français éthique et OTC stagnant • Une politique du médicament de plus en plus volontariste • Une industrie confrontée aux défis de l’innovation Agenda IMS Health 2011 • Une croissance mondiale

SUMMARY May 2016 Merger was announced - Quintiles agreed to

merge with health care information company IMS Health (IMS) in a deal worth about $9 billion The combined company which will have a market value of nearly $18 billion will offer drug and medical device makers services ranging from helping run clinical trials to tracking sales once a product has hit the market After the deal IMS

IMS HealthIMS Health

May 1 2016 · (in millions) 2016 2015 Net Cash (Used in) Provided by Operating Activities $ (15) $ 30 Capital expenditures (13) (9) Additions to computer software (26) (23) Free Cash Flow $ (54) $ (2) Cash interest ppyayments 33 30 Cash tax payments net of refunds 19 16 Acquisition related charges (1) 12 8 Severance transaction & other payments 29 7

IMS HealthIMS Health

Jul 1 2016 · June 30 Six Months Ended June 30 (in millions) 2016 2015 2016 2015 Net Income $ 24 $ 47 $ 67 $ 345 Provision for (benefit from) income taxes 7 13 27 (227) Other (income) loss net 2 (6) 7 (10) Interest expense 47 43 93 80 Interest income (1) (1) (2) (1) Depreciation and amortization 88 81 175 177 Deferred revenue purchase accounting

Perspective on Prescription Drug Costs

1 -5 0 5 10 15 20 0 50 100 150 200 250 300 350 400 450 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Net Spending Invoice to Net Spending Difference

The Trillion Dollar Market for Medicines: Characteristics

analysis performed by IMS Health and published as IMS Market Prognosis reports for 42 countries 11 regions and globally • Methodology for each country forecast combines: ?Collection of historical data by sector as captured by IMS audits estimates of unaudited market sectors and 5 most significant macroeconomic indicators based on

Health policy in France - OECD

Health policy in France January 2016 www oecd org/health While the prevalence of obesity in France remains below the OECD average (14 5 versus 19 0 ) it has grown fairly quickly over the past ten years Obesity means higher risk of chronic illnesses (hypertension

Situational Analyses on Health Technology Assessment - EFPIA

Note: IMS defines specialty therapies as medicines that treat specific complex chronic diseases with 4 + of the following attributes: initiated by a specialist; generally not oral; require special handling; unique distribution; high expense; warrants intensive patient counseling; requires reimbursement assistance

June 2016 - Morning Consult

• Over 135 clinical trials for additional indications across 30 tumor types exist between the two currently approved PD-1 inhibitors • The promising PD-L1 inhibitor atezolizumab has ongoing